Rosacea is a chronic relapsing inflammatory skin disease with high prevalence world- 
| INTRODUCTION
Today, 2%-10% of the general population is believed to suffer from rosacea. 1 Uncontrolled vasodilation, inflammation and later fibrosis associated with glandular hyperplasia comprise rosacea, which clinically and differentially presents as transient or persistent erythema, telangiectasia, papules, pustules and/or phymata, depending on the subtype 2 ( Fig. 1) . Based on what is now known about rosacea cell biology, activation of various receptors on multiple cell types by rosacea "triggers" and release of disparate mediators within the skin appear to be the initiating events leading to clinical manifestation of rosacea.
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Differentiating these receptor-specific activation pathways can distinctly explain both vasodilation and inflammation as primary outcomes.
Furthermore, neurological, innate and adaptive immune mediators reported to be elevated across rosacea subtypes [6] [7] [8] are present in chronological pathways that, when integrated, may explain a novel step-by-step progression of the condition from initiation to phenotype.
Multiple treatment modalities exist for rosacea. Current approved therapies including topical metronidazole, azelaic acid, ivermectin and oral tetracyclines are generally effective at inhibiting the inflammatory pathways involved in rosacea. Erythema and phymatous manifestations, however, lack comprehensive pharmacologic treatment options.
The intention of this review is to integrate the different pathways of the involved biological systems responsible for the different clinical facets of rosacea and, from this information, to identify the remaining scientific questions critical for a deeper understanding of rosacea and for future development of improved, pathomechanism-based therapies.
| ROSACEA PATHOPHYSIOLOGY

| Triggering innate and neural receptors
Common triggers for rosacea are well described (Table S1 ). 9 Cutaneous receptors that are overexpressed in rosacea skin and responsive to trigger encounter include Toll-like receptor (TLR) 2, 3 the nucleotide-binding oligomerization domain (NOD)-like receptor NALP3 6 and several members of the transient receptor potential (TRP) family of ion channels. 4, 5 TLR2 is a pattern recognition receptor (PRR) expressed on the cellular membrane of keratinocytes, macrophages, mast cells and a variety of other cells present in skin that responds to extracellular pathogen-or damage-associated molecular patterns (e.g. bacterial lipoproteins, ultraviolet light). 10 Receptor activation results in production of the innate immune peptide cathelicidin, 3 as well as activation of the transcription factor nuclear factor-kappa B (NF-κB), cytokines and chemokines. 11, 12 NALP3 is an intracellular counterpart to TLR2 that resides in Sensitivity to rosacea triggers through upregulation of triggerresponsive receptors is a logical first step in initiation and perpetuation of rosacea. The variety of receptors that appear to be involved may help to explain the unique trigger profiles of individual rosacea sufferers (Table S1) . Furthermore, pathophysiological outcomes may differ depending on individual receptor activation profiles and downstream cellular activation targets (Fig. 2) , providing a hypothesis for the phenotypic variability that confounds rosacea. 
| Cathelicidin-mediated inflammation
| Inflammasome activation
The cathelicidin activation pathway is currently the best understood pathway in rosacea, but it is not singularly responsible for rosacea (Fig. 3 ). In addition to vasodilation, TRP and neuropeptide expression may also be linked to a variety of inflammatory processes active in rosacea. TRP and PGE2 can exhibit mutually enhanced function in the presence of one another, resulting in a lower threshold for TRP activation and increased pain sensation. 40, 41 Mast cell activation by neuropeptides can result in the release of histamine, which may influence vasodilation; tryptase, a chemotactic agent for fibroblasts; and MMP. 7, 18, 42 Both fibroblasts and MMP have been implicated in fibrotic processes in rosacea skin and are surprisingly present in even the earliest stages of rosacea. 7, 43 Neuropeptides can also stimulate IL-1β production 44 and influence leucocyte migration 
| Neurogenic inflammation
Proposed innate pathophysiological pathways in rosacea encompass skin, immune cells, nerves, and vessels. Trigger activation of TLR2 on keratinocytes or possibly mast cells yields active LL-37, whose actions may result in angiogenesis and leucocyte chemotaxis. Activation of NALP3 in the IL-1β inflammasome complex in macrophages or keratinocytes influences expression or secretion of downstream inflammatory modulators that manifest clinically in the formation of pustules, papules, and sensations of heat and pain, processes that may be further amplified by TLR2 activation or neuropeptides. Neuropeptides, which are produced in response to triggering of TRP ion channels on neuronal and non-neuronal cells, can directly or indirectly result in vasodilation and mast cell activation. Other vascular effects and fibrotic processes can be perpetuated by inflammatory intermediates synthesized in response to these cellular activities through upregulation of vascular adhesion molecules, 45 suggesting neurogenic inflammatory processes are also likely active (Fig. 3 ). Demodex mites are present at a higher density in rosacea-affected skin, 53 and others have hypothesized an immune defect may allow its proliferation in this setting. 54 Individuals with demodicosis (Demodex infestation) display a reduction in both CD4 + and CD8 + T-cell subsets compared to controls 55, 56 ; furthermore, a protective genetic association between the presence of CD8 + T cells and severity of demodicosis has been established. 57 Rosacea is commonly associated with T-cell immunosuppression, which can occur following infection (e.g. HIV) 58 or therapeutic intervention (e.g. corticosteroids, calcineurin inhibitors, phototherapy). [59] [60] [61] These same individuals also commonly present with Demodex infestation. [58] [59] [60] 62 These findings suggest a parallel may exist between Demodex proliferation and reduced cytotoxic CD8 + T-cell activity in rosacea, while an exacerbated Th1/Th17 response may contribute importantly to rosacea inflammation (Fig. 4) . (Fig. 4) .
| Imbalanced adaptive immunity
| PHENOTYPES OF ROSACEA
Clinically, rosacea exhibits a unique erythematous phenotype compared to other common inflammatory skin diseases. The scale characteristics of eczemas, psoriasis or chronic discoid lupus erythematodes are absent in rosacea, and no comedones, a different age peak and Ocular manifestations are also common and include blepharitis and conjunctivitis, although not described in detail here.
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Prevailing combinations of clinical signs are categorized into designated subtypes; however, multiple subtypes commonly coexist in a single patient (Fig. 1) . Rosacea is not a static condition, and each individual case can be unique not only in its presentation but also in its triggers, chronicity and progression. The mediators purportedly responsible for individual signs and symptoms are summarized in Table S2 .
The genetics of rosacea are poorly understood. A study in twins suggests a 46% genetic contribution
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; furthermore, a genomewide association study confirmed that three human leucocyte antigen (HLA) alleles and a small nucleotide polymorphism are genetically linked to rosacea. 69 Interestingly, rosacea-associated HLA genes have also been identified in other disorders with inflammatory, neural, granulomatous and ocular manifestations. (Fig. 2) . 70, 71 and is the second most common trigger reported by rosacea patients (Table S1 ).
Although TRP channel activation clinically manifests as erythema via neuropeptide activity, and PRR activation classically results in inflammation, a large overlap exists in the cells that co-express these receptors, the triggers that co-activate them and the activated physiological pathways that result in rosacea's clinical presentation.
Therefore, while one trigger may favour a clinical sign (e.g. heat and erythema), it is impossible to separate the phenotypes of rosacea by trigger, physiological response or subtype due to the inherent commonality of the activated pathways (Fig. 2 ).
| The acute versus persistent sufferer
Rosacea is a chronic condition that can progress or worsen with time. Telangiectasia, the second vascular component of rosacea, comprises small, fixed vessels that are not vasoactive. It is unknown whether telangiectasia arises from abnormal angiogenesis or whether they are pre-existing vessels that are visible due to irreparable damage to the connective tissue or the vessel by the proteolytic and oxidative processes described above. Both theories explain worsening of telangiectasia as rosacea progresses; however, results from a recent study by Helfrich and colleagues argue against an impaired extracellular matrix as the cause of telangiectasia development. 16 Similarly, angiogenesis does not appear to be a critical factor in ETR.
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The same cellular pathways are elevated in erythematotelangiectatic and papulopustular rosacea; however, not every rosacea patient presents with papules and pustules. The severity of both subtypes directly correlates with the intensity of perivascular and perifollicular lymphocytic infiltrate. 73 Typically, higher expression of inflammatory mediators is reported in the papulopustular form, 6-8 which suggests
an inflammatory threshold must be reached for its manifestation or to generate perilesional erythema surrounding papules and pustules. As higher Demodex loads are also reported in papulopustular rosacea, (Table S2 and Fig. 5 ).
| TARGETED MECHANISMS OF CURRENT ROSACEA THERAPEUTICS
Besides trigger avoidance, the most common treatment approaches to rosacea are pharmacologic in nature. Emollients and sunscreens are recommended for all rosacea patients to stabilize barrier dysfunction and to help prevent photo-aggravation, respectively, and are discussed elsewhere. 76 Additional therapeutics include pharmacologically F I G U R E 5 Positive feedback loops amplify inflammation to explain chronicity of rosacea. Following receptor activation by rosacea triggers, sustained activation of peptides, cytokines and enzymes by coincident mediators may perpetuate inflammatory processes distinct topical and oral agents, administered alone or in combination.
A favourable prognosis exists for patients with papulopustular presentation, while patients with underlying persistent erythema or phymata, with or without inflammatory lesions, are much more refractory to treatment. 77 Approved systemic and topical therapies are discussed below; additional experimental therapies are summarized in Table 1 .
| Oral tetracyclines
Oral tetracycline-class anti-inflammatories are commonly used to treat papulopustular rosacea, and a 40 mg modified-release doxycycline capsule is approved for its treatment. Phase III studies reported mean lesion count reductions of 47.5%-59% (mean lesion count 20)
in 269 patients after 16 weeks.
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The efficacy of tetracyclines in the treatment of rosacea is explained by its wide-ranging inhibition of inflammatory mediators and cellular processes critical to the innate, adaptive and angiogenic pathways described in rosacea 17,79-86 ( Table 1 ). The molecular mechanism of tetracyclines responsible for its broad activity includes direct transcriptional inhibition, inhibition of enzymes such as protein kinase C and, most notably, chelation of divalent cations (e.g. Ca Recently, the Nobel Prize in Physiology or Medicine was awarded for the beneficial impact of avermectin to eradicate parasitic diseases. Its derivative ivermectin exhibits similar antiparasitic activity by binding to glutamate or γ-aminobutyric acid (GABA) in the peripheral motor synapses of neurons, resulting in permanent opening of anion channels and subsequent paralysis of the parasite. 88 In addition to eliminating Demodex, the mechanism of ivermectin in rosacea is now thought to be twofold, as several anti-inflammatory properties have been identified in vitro and in small animal models [89] [90] [91] (Table 1 ).
The molecular mechanisms resulting in the anti-inflammatory properties of ivermectin are likely inhibition of phosphorylation of the mitogen-activated protein kinases (MAPKs), JNK and p38 as well as inhibition of translocation of the transcription factor NF-κB. 90, 91 NF-κB-responsive genes include TLR2, IL-1β, IL-8, TNF and COX-2.
| Topical azelaic acid
Azelaic acid has proven clinical efficacy in the treatment of papulopustular rosacea, as studies with topical azelaic acid 15% gel resulted in mean lesion count reductions of 50%-57.9% (mean lesion count 18) in 333 patients after 12 weeks. 92, 93 Like ivermectin, the molecular mechanism by which azelaic acid exerts its activity appears to be related to inhibition of NF-κB translocation and p38 signalling, 94 resulting in anti-inflammatory activities [93] [94] [95] (Table 1 ).
| Topical metronidazole
Topical metronidazole (0.75% and 1%) is also approved for the treatment of papulopustular rosacea. Phase III studies with metronidazole 1% gel reported mean lesion count reductions of 50.7% (mean baseline lesion count 18.3) in 557 patients after 10 weeks. 96 Unlike other topical rosacea therapeutics with broad activity, the mechanism of metronidazole appears to be highly targeted to ROS ( Table 1) .
Inhibition of ROS production and scavenging of secreted ROS have both been reported. 
| Topical brimonidine
Unlike the other therapeutics discussed, brimonidine is approved for symptomatic relief of the erythema of rosacea. Clinical studies with brimonidine 0.33% gel report significant reductions in erythema Delivery of the therapeutic agent to the location in the skin where each target or process is active is also required for the proposed inhibitory activities to take place. Oral agents delivered systemically likely have the highest concentration at the capillary beds from which they diffuse to the more superficial layers of the skin. Alternatively, topical agents have the highest concentration at the skin surface and within dermal appendages, with variable penetration to deeper layers of the skin.
With these considerations in mind, effective therapeutic approaches will likely combine agents that can effectively downregulate the primary effectors in rosacea, with delivery to the appropriate locus within the skin. Development of new therapeutic tools and clinical studies evaluating therapeutic agents in combination will be required to verify the most effective approach.
The TRP ion channel activation pathway is largely untouched by current pharmacologic agents. With the exception of brimonidine, the compounds described above do not have a significant impact on erythema of rosacea. This suggests that TRP activation and subsequent neuropeptide production, rather than inflammation, is predominantly responsible for the acute vascular effects observed in rosacea.
Therapeutic approaches to inhibit neuroinflammation and neurovascular dysregulation in rosacea are currently under way. Antagonists to TRP ion channels or neuropeptides may be promising avenues to treat rosacea in the future.
| CONCLUSIONS AND FUTURE DIRECTIONS
Novel insights into molecular components that intricately dictate the pathophysiology, clinical presentation and progression of the common cutaneous subtypes of rosacea are summarized here. Several open questions must be answered before we will thoroughly understand this complex disease (Table 2) . 
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article. Table S1 . Receptors are activated by common rosacea triggers. 
